FIELD: medicine, ophthalmology, medicinal biochemistry.
SUBSTANCE: invention relates to manufacturing ophthalmic composition used for reducing intraocular pressure. Invention proposes using inhibitors of glycogen synthase kinase-3. Proposed composition provides reducing intraocular pressure by increasing intraocular liquid efflux and to prevent loss of retina ganglion cells.
EFFECT: valuable medicinal properties of inhibitors.
19 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHIBITORS OF HYSTONE DEACETYLASE FOR TREATMENT OF DEGENERATIVE EYE DISEASES | 2003 |
|
RU2324483C2 |
| PHTHALAZINE KETONE DERIVATIVE, METHOD OF OBTAINING THEREOF AND PHARMACEUTICAL APPLICATION | 2011 |
|
RU2564527C2 |
| DERIVATIVES OF 4-HYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE-1-YL-UREA AND THEIR USE IN TREATMENT, INTER ALIA, DISEASES OF RESPIRATORY TRACT | 2011 |
|
RU2586333C1 |
| 1,5,6-SUBSTITUTED 2-OXO-3-CYANO-1,6A-DIAZATETRAHYDROFLUORANTHENES | 2006 |
|
RU2389730C2 |
| PYRASOLE[3,4-b]PYRIDINE COMPOUNDS AND THEIR APPLICATION AS PHOSPHODIESTERASE INHIBITORS | 2003 |
|
RU2348633C2 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | 2011 |
|
RU2623427C2 |
| 2-PYRIDYL-SUBSTITUTED IMIDAZOLES AS THERAPEUTIC ALK5 AND/OR ALK4 INHIBITORS | 2011 |
|
RU2518069C1 |
| FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | 2012 |
|
RU2650641C2 |
| APPLICATION OF SERUM AMYLOID A GENE FOR DIAGNOSIS AND THERAPY OF GLAUCOMA AND IDENTIFICATION OF ANTIGLAUCOMATOUS AGENT | 2007 |
|
RU2461378C2 |
| DIAMINOTRIAZOLES, SUITABLE AS INHIBITORS OF PROTEIN KINASES | 2003 |
|
RU2350606C2 |
